Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity
Joseph M. Gozgit, Melissa M. Vasbinder, Ryan Abo, et al.
Cancer Cell (2021) Vol. 39, Iss. 9, pp. 1214-1226.e10
Closed Access | Times Cited: 115

Showing 1-25 of 115 citing articles:

Exploring treatment options in cancer: Tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 132
Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment
John D. Klement, Priscilla S. Redd, Chunwan Lu, et al.
Cancer Cell (2023) Vol. 41, Iss. 3, pp. 620-636.e9
Open Access | Times Cited: 71
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
Antonella Padella, Andrea Ghelli Luserna di Rorà, Giovanni Marconi, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 69
ADP-ribosylation from molecular mechanisms to therapeutic implications
Marcin J. Suskiewicz, Evgeniia Prokhorova, J.G.M. Rack, et al.
Cell (2023) Vol. 186, Iss. 21, pp. 4475-4495
Open Access | Times Cited: 67
The DNA Damage Response and Inflammation in Cancer
Vanessa Klapp, Beatriz Álvarez-Abril, Giuseppe Leuzzi, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1521-1545
Open Access | Times Cited: 54
Type I interferon and cancer
Peter Holíček, Emma Guilbaud, Vanessa Klapp, et al.
Immunological Reviews (2023) Vol. 321, Iss. 1, pp. 115-127
Open Access | Times Cited: 42
Design, Synthesis, and Structure–Activity Relationship of Novel Pyridazinone-Based PARP7/HDACs Dual Inhibitors for Elucidating the Relationship between Antitumor Immunity and HDACs Inhibition
Ji‐Long Duan, Chenchen Wang, Yinghui Yuan, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 4950-4976
Closed Access | Times Cited: 31
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers
Linjie Luo, Khandan Keyomarsi
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 6, pp. 607-631
Open Access | Times Cited: 42
Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics
Iain A. Richard, Joshua T. Burgess, Kenneth J. O’Byrne, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 9
Open Access | Times Cited: 40
In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases
Thomas Kerzel, Giovanna Giacca, Stefano Beretta, et al.
Cancer Cell (2023) Vol. 41, Iss. 11, pp. 1892-1910.e10
Open Access | Times Cited: 39
PARPs and ADP-ribosylation: Deciphering the complexity with molecular tools
Morgan Dasovich, Anthony K. L. Leung
Molecular Cell (2023) Vol. 83, Iss. 10, pp. 1552-1572
Open Access | Times Cited: 33
Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer
Qingyun Zhu, Qiuzi Dai, Lei Zhao, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 11
Targeting chromosomal instability in patients with cancer
Duaa H. Al-Rawi, Emanuele Lettera, Jun Li, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 9, pp. 645-659
Closed Access | Times Cited: 11
NAT10-mediated upregulation of GAS5 facilitates immune cell infiltration in non-small cell lung cancer via the MYBBP1A-p53/IRF1/type I interferon signaling axis
Zimu Wang, Jing Luo, Hairong Huang, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Parps in immune response: Potential targets for cancer immunotherapy
S Wang, Jingling Huang, T. X. Zeng, et al.
Biochemical Pharmacology (2025) Vol. 234, pp. 116803-116803
Closed Access | Times Cited: 1
Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance
Limin Wang, Pingyuan Wang, X. T. Chen, et al.
EMBO Molecular Medicine (2023) Vol. 15, Iss. 3
Open Access | Times Cited: 20
PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models
Chun Wai Wong, Christos Evangelou, Kieran N. Sefton, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 20
Targeting STING in cancer: Challenges and emerging opportunities
Kexin Zhao, Jiaojiao Huang, Yue Zhao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 188983-188983
Closed Access | Times Cited: 18
Pharmacological Polarization of Tumor‐Associated Macrophages Toward a CXCL9 Antitumor Phenotype
Noah Enbergs, Elias A. Halabi, Anne‐Gaëlle Goubet, et al.
Advanced Science (2024) Vol. 11, Iss. 15
Open Access | Times Cited: 6
Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules
Maria Giulia Nizi, Mirko M. Maksimainen, L. Lehtiö, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7532-7560
Open Access | Times Cited: 24
Structurally distinct PARP7 inhibitors provide new insights into the function of PARP7 in regulating nucleic acid-sensing and IFN-β signaling
Daniel J. Sanderson, Kelsie M. Rodriguez, Daniel S. Bejan, et al.
Cell chemical biology (2022) Vol. 30, Iss. 1, pp. 43-54.e8
Open Access | Times Cited: 23
Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
Xiaopeng Peng, Wanyi Pan, Feng Jiang, et al.
Pharmacological Research (2022) Vol. 186, pp. 106529-106529
Closed Access | Times Cited: 22
Discovery of the Potent and Highly Selective PARP7 Inhibitor as a Novel Immunotherapeutic Agent for Tumors
Hong‐Feng Gu, Wenxin Yan, Yong Wang, et al.
Journal of Medicinal Chemistry (2022) Vol. 66, Iss. 1, pp. 473-490
Closed Access | Times Cited: 22
[1,2,4]Triazolo[3,4-b]benzothiazole Scaffold as Versatile Nicotinamide Mimic Allowing Nanomolar Inhibition of Different PARP Enzymes
Sudarshan Murthy, Maria Giulia Nizi, Mirko M. Maksimainen, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 2, pp. 1301-1320
Open Access | Times Cited: 14
PARP7-mediated ADP-ribosylation of FRA1 promotes cancer cell growth by repressing IRF1- and IRF3-dependent apoptosis
Patrick Manetsch, Flurina Böhi, Kathrin Nowak, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 49
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top